A Phase III, Randomized, Multicentric, Open-label, Equivalence Design Study to Compare the Safety and Efficacy of USV's Pegfilgrastim and Neulastim in Patients Receiving Doxorubicin and Docetaxel as a Combination Chemotherapy for Breast Cancer

Trial Profile

A Phase III, Randomized, Multicentric, Open-label, Equivalence Design Study to Compare the Safety and Efficacy of USV's Pegfilgrastim and Neulastim in Patients Receiving Doxorubicin and Docetaxel as a Combination Chemotherapy for Breast Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Pegfilgrastim (Primary) ; Docetaxel; Doxorubicin
  • Indications Neutropenia
  • Focus Registrational; Therapeutic Use
  • Sponsors GVK BIO; USV
  • Most Recent Events

    • 06 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 12 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top